A clinical trial to study the effect of two drugs vatari guggulu and mahaushadhi kwatha in patients suffering with amavata (rheumatoid arthritis).

CLINICAL STUDY ON COMBINED EFFECTIVENESS OF VATARI GUGGULU AND MAHAUSHADHI KWATHA IN AMAVATA (RHEUMATOID ARTHRITIS)

Status

Recruiting

Phases

Phase 2

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2018/05/014035

Enrollment

Registered

2018-05-22

Start date

Unknown

Completion date

Unknown

Last updated

2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: null- Amavata (Rheumatoid arthritis)

Interventions

Intervention1: Vatari Guggulu and Mahaushadhi kwatha: Vatari Guggulu 1 gm thrice daily for 15 days Mahaushadhi kwatha 15 ml thrice daily for 15 days Control Intervention1: NIL: NIL

Eligibility

Inclusion criteria

Inclusion criteria: 1.Amavata with features of rheumatoid arthritis as specified in 2010 ACR-EULAR classification criteria for Rheumatoid arthritis with less than 5 years of chronicity (Parameters in ACR-EULAR criteria: Duration of symptoms, joint distribution, serology, acute phase reactants) 2. Patients aged between 20-60 years 3. Patients of either gender 4. Patient willing to participate in the study and ready to sign informed consent form

Exclusion criteria

Exclusion criteria: 1.Hypertension, diabetes mellitus and other systemic disorders 2.Impaired renal, hepatic and cardiac function 3.Systemic arthritis (gout, tubercular arthritis, Systemic lupus erythematosus, psoriatic arthritis) 4.Swan neck deformity, Boutonniere deformity, rheumatic nodules 5. Pregnant and lactating woman

Design outcomes

Primary

Measure	Time frame
Signs and symptoms of amavata (rheumatoid arthritis) will be assessed by giving suitable scoring at three intervals namely before, 7th day and 15th day of treatment. The disease activity of the patient will be assessed by disease activity score of 28 joints (DAS28), simple disease activity index (SDAI), acute phase reactants (Erythrocyte sedimentation rate and c-reactive protein) and early morning stiffness in minutes Timepoint: Signs and symptoms of amavata (rheumatoid arthritis) will be assessed by giving suitable scoring at three intervals namely before, 7th day and 15th day of treatment. The disease activity of the patient will be assessed by disease activity score of 28 joints (DAS28), simple disease activity index (SDAI), acute phase reactants (Erythrocyte sedimentation rate and c-reactive protein) and early morning stiffness in minutes	—

Measure

Time frame

Signs and symptoms of amavata (rheumatoid arthritis) will be assessed by giving suitable scoring at three intervals namely before, 7th day and 15th day of treatment. The disease activity of the patient will be assessed by disease activity score of 28 joints (DAS28), simple disease activity index (SDAI), acute phase reactants (Erythrocyte sedimentation rate and c-reactive protein) and early morning stiffness in minutes Timepoint: Signs and symptoms of amavata (rheumatoid arthritis) will be assessed by giving suitable scoring at three intervals namely before, 7th day and 15th day of treatment. The disease activity of the patient will be assessed by disease activity score of 28 joints (DAS28), simple disease activity index (SDAI), acute phase reactants (Erythrocyte sedimentation rate and c-reactive protein) and early morning stiffness in minutes

—

Secondary

Measure	Time frame
NILTimepoint: NIL	—

Countries

India

Contacts

Public ContactDr Girish K J

Sri Dharmasthala Manjunatheshwara College of Ayurveda and Hospital

vibhupowar43@gmail.com7045221909

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026